Rue André Fauchillestraat, 17  -  BRUXELLES 1150 BRUSSELS  -  BELGIUM   

      Service Clientèle:   02 736.62.18      Klanten Dienst:      02 735.40.62      Fax : 02 742.13.15

email : Michelle Thiriaux       Message to me

 

 **************************************************    

Very important notice for export

************************************************** 

A new web site with full information concerning our Food and Feed program is coming soon.

We wish you a Merry Christmas and an Happy New Year.

 

 

Food & Feed Analysis

With the exclusive distribution in Belgium of the product lines of :

R - Biopharm AG   www.r-biopharm.de


 

 Also Fapas  www.fapas.com

 

 

 And    DSM    -   Rotronic

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Prolactin                         Coated Tubes

Immunoradiometric assay kit for the quantitative measurement of human Prolactin                                         (PRL).

BL-25-CT: 100 determinations

for in vitro diagnostic use only

 

1. Summary and background of the test:

Prolactin (PRL) is e polypeptide hormone (molecula weight 20,000) secreted by the pituitary gland which plays a key role in the development of the mammary gland, the production and secretion of milk and the control of male and female gonadal functions.Prolactin secretion is under hypothalamic control exerted directly by dopamine, several prolactin releasing factors (PRF) and perhaps VIP (vasoactive intestinal polypeptide) or a closely related peptide. TRH also acts directly at the pituitary level to stimulate prolactin release but its physiological role in the control of prolactin secretion has not been established yet. Several factors, involving serotoninergic or noradrenergic pathways are also invoved in the control of prolactin secretion. The plasma concentration of prolactin increases in various physiological situations sush as stress, pregnancy and lactation. Physiological levels fluctuate according to a nycthemeral rhythm, a significant rise being observed at night. Drugs with anti-dopamine activity (psychotropic agents) and ovulatory supressants, increase prolactin secretion.

 

2. Principle of the test :

The Bio-Line Prolactin-Irma is an immunoradiometnc assay based on coated-tube separation in which several monoclonal antibodies directed against distinct epitopes of Prolactin have been used.. Mabs1, the capture antibodies, are attached to the lower and inner surface of the plastic tube. Standards or samples added to the tubes will at first show low affinity for Mabs1. Addition of Mab2, the signal antibody labelled with 125I, will complete the system and trigger the immunological reaction. After washing, the remaining radioactivity bound to the tube reflects the antigen concentration. The use of several distinct Mabs avoids hyperspecificity.

 

3. Precautions:

1. Radioactive material: Radioactive material may be received, acquired, possessed and used only by physicians, clinical laboratories, or hospitals for "In-Vitro" clinical or laboratory tests not involving internal or external administration of the material, or the radiation therefrom, to human beings or animals.

Compliance with these basic rules of radiation safety should provide adequate protection:

1. Do not eat, drink, smoke, or apply cosmetics in areas where radioactive material is used.

2. Do not pipet by mouth reagents containing radioactive materials.

3. Wear protective clothing; i.e., lab coats and disposable gloves, in order to avoid direct contact with radioactive reagents.

4. Work with radioactive materials should be performed in a designed area.

5. Radioactive materials should be stored in an acceptable location.

6. A log should be kept for receipt and disposal of radioactive materials.

7. Radioactive spills or accidents should be taken care of immediately according to established procedures.

            8. Disposal of radioactive materials must comply with prevailing regulations and guidelines of the agencies holding                 jurisdiction over the laboratory.

2. Sodium azide: Sodium Azide, used as a bacteriostatic agent, is toxic in acid medium. In addition, it may form potentially explosive lead or copper azides. To avoid dangerous deposits, waste solutions should be flushed away with large volumes of water.

3. Hepatitis and Acquired Immune Deficiency Syndrome (HTLV-III): All Bio-Line reagents included in this kit have been tested and found to be non reactive for hepatitis B surface antigen. They have also been screened and determined to be non-reactive for HTLV-III antibody. However, human serum products should be handled as if potentially capable of transmitting hepatitis, Acquired Immune Deficiency Syndrome, or other infectious agents.

 

4. Materials provided:

Kit contains sufficient reagents for 100 determinations.

1. Human serum with sodium merthiolate and azide based standards & control: 8 lyophilised vials to reconstitute with 0.5 ml exept the standard with 2.0 ml.

                        See exact values on vial labels.

2. 125I-Monoclonal-anti-Prolactin tracer: 2 vials (red solution) containing 10.5 ml. Activity < 4.75 µCi or 175 kBq.

3. Coated tubes: 2 x 50 tubes, coated with Anti-Prolactin monoclonal antibodies.

4. Wash solution concentrate: 1 vial of 10 ml of concentrate, to be diluted into 700 ml distilled water and stored at 4° C.

Reagents provided should be stored at 2o - 8o C.

Refer to the expiration date on the kit label for stability.

 

5. Materials required but not provided:

The following material is required but not provided in the kit:

1. Distilled water

2. Pipettes for delivery of: 25, 200 and 500 µl, 2 ml (the use of accurate pipettes with disposable plastic tips is recommended)

3. 5 ml automatic syringe (Cornwall type) for washing

4. Aspiration system (optional)

5. Gamma counter, set for 125I counting and Vortex mixer and magnetic stirrer.

 

6. Specimen collection and preparation:

Serum or plasma :

             Serum and plasma must be kept at 2 – 8°C.

If the test is not run within 24 hours, storage at –20°C is recommended and will not result in loss of immuno-reactivity for at least 6 months.

Serum or EDTA plasma provide similar results.

                    Y(serum) = 1.09x (hep. plasma) + 0.05 r = 0.95 n = 30

                    Y(serum) = 0.96x (EDTA plasma) + 0.14 r = 0.98 n = 30

            Do not use haemolysed samples.

 

7. Assay procedure:

             Do not use the kit or components beyond expiration date. Do not mix materials from differents kit lots. Bring all the                 reagents to room temperature prior to use. Thoroughly mix all reagents and samples by gentle agitation or swirling.

Use a clean disposable pipette tip for addition of each different reagent and sample in order to avoid cross-contamination.

High precision pipettes or automated pipetting equipment will improve the precision. Respect the incubation times.

Prepare a standard curve for each run, do not use data from previous runs.

1. Label coated tubes in duplicate for each standard, sample, control. For determination of total counts, label 2 normal tubes.

2. Vortex mix briefly standards, samples, controls and dispense 25 µl of each into the respective tubes.

            3. Dispense 200 µl of tracer into each tube, including the ones for Total count.

4. Shake the rack containing the tubes gently by hand.

5. Incubate for 2 hours at room temperature.

6. Aspirate (or decant) the content of each tube (except total counts). Be sure that the plastic tip of the aspirator reaches the bottom of the coated tube in order to remove all the liquid.

7. Wash the tubes with 2 ml Wash Solution (except total counts). Avoid foaming during the addition of the Wash Solution.

8. Aspirate (or decant) the content of each tube (except total counts).

9. After the washing let the tubes standing upright for 2 minutes and aspirate the remaining drop of liquid.

            10. Count the tubes in a gamma counter for 60 seconds.

 

8. Prolactin Coated Tubes Flow chart

 
 

Total Counts (µl)

Standards (µl)

Sample(s) (µl)

Standards (0-6)

Samples

Tracer

-

-

200

25

-

200

-

25

200

Incubation

2h at Room Temperature

Separation

Washing solution (ml)

Separation

-

-

-

Aspirate (or decant)

2.0

Aspirate (or decant)

Counting

Count tubes for 60 seconds

 

9. Data table (example)

PRL-IRMA

Cpm

B/T (%)

Total count

Standard

 

0ng/ml

3.0ng/ml

10.0ng/ml

30.0ng/ml

100.0 ng/ml

200.0 ng/ml

148445

378

1911

5411

14588

37685

51640

 

0.25

1.29

3.64

9.82

25.38

34.78

 

10. Calculation of results:

On semilogarithmic or linear graph paper plot the c.p.m. (ordinale) for each standard against the corresponding concentration of PRL (abscissa) and draw a standard curve through the standard points, reject the obvious outliers. Read the concentration for each control and sample by interpolation on the standard curve. Computer assisted data reduction will simplify these calculations.

 

11. Expected Values:

 

N

Mean

(ng/ml)

Range

(ng/ml)

Males

Pre-menopausal women

Post-menopausal women

97

95

47

4.8

8.6

6.1

1.8 – 15.9

2.7 – 19.7

1.9 – 17.9

 

12. Specific performance characteristics:

A. Minimum Detectable Concentration

The MDC is estimated at 0.35 ng/ml and is defined as the concentration of PRL which corresponds to a cpm level 2 standard deviations above the mean of 20 replicates of the zero standard.

            B. Precision

            INTRA ASSAY                                                                          INTER ASSAY

Serum

Replicate

X±S.D. (ng/ml)

CV (%)

Serum

Replicate

X±S.D.

(ng/ml)

CV (%)

A

B

20

20

7.5 ± 0.3

26.6 ± 1.7

4.0

6.4

A

B

10

10

7.0 ± 0.50

26.6 ± 1.8

7.1

6.8

C. Speciflcity

Cross-reactive hormones were added to a low PRL value serum and to a high value standard (100 ng/ml). The apparent PRL response was measured.

Added hormones to a Low

PRL value serum (2.3 ng/ml)

Observed PRL values

(ng/ml)

Added hormone to a High PRL value serum (100 ng/ml)

Observed PRL values

(ng/ml)

-

LH

FSH

HCG

HPL

HGH

TSH

170 mIU/ml

150 mIU/ml

100.000 ng/ml

10.000 ng/ml

1000 ng/ml

200µIU/ml

2.2

2.3

2.2

2.3

2.3

2.6

2.6

-

LH

FSH

HCG

HPL

HGH

TSH

170 mIU/ml

150 mIU/ml

100.000 ng/ml

10.000 ng/ml

1000 ng/ml

200µIU/ml

100

97

97

97

100

103

100

This shows that PRL-Irma does not cross react with LH, FSH, TSH, hCG, hPL and hGH.

D. Accuracy

                                        RECOVERY TEST

Sample

Added PRL(ng/ml)

Recovered PRL (ng/ml)

Recovery (%)

Serum

 

 

 

2

5

10

20

50

1.8

5.0

9.8

19.5

45.6

90.0

100.0

98.0

97.5

91.2

 

                                        DILUTION TEST

Sample

Dilution

Theoretical Concent

(ng/ml)

Measured Concent.

(ng/ml)

Serum 1

 

 

 

 

Serum 2

 

1/1

1/2

1/4

1/8

1/16

1/4

1/8

1/16

144.0

72.0

36.0

18.0

9.0

 

22.9

11.4

5.7

2.9

1.4

144.0

74.5

35.2

16.9

8.4

 

22.9

11.6

6.7

3.1

1.5

 

13. Bibliography

1. ARCHER D.F. (1977)Current concepts of prolactin physiology in normal and abnormal conditions.Fretil. Steril. 28 :125

2. LAUFER N., BOTERO-RUIZ W., DE CHEMEY A.H. et al. (1984)Gonadotropin and prolactin levels in follicular fluid of human ova successfully fertilized in vitroJ. Clin. Endocrinol. Metab., 58 :430

3. LEONG D.A., FRAWLEY L.S., NEIL J.D. (1983)Neuroendocrine control of prolactin secretions.An. Rev. Of Physiol. 45 :109

4. SEPPALA M. (1978)Prolactin and female reproduction.An ; Clin. Res. 10 :164

5. TAYLOR T.J., TROUSON A., BESANKO M., BURGER H.G., STOCKDALE J. (1986)Plasma progesterone and prolactin changes in superovulated women before, during and immediately after laparoscopy for in vitro fertilization and their relation to pregnancy. Fertil. And Steril. 45 :680

6. TYSON J.E. (1980)Changing role of placental lactogen and prolactin in human gestation.Clin. Obstet. Gynecol. 23 :737

7. KAMEL M.A. et al. (1994)Comparison between prolactin, gonadotropin and steroid hormones in serum and follicular fluid after stimulation with gonadotrophin-releasing hormone agonist and human menopausal gonadotrophin for an in-vitro fertilization program.Hum. Reprod. 9 (10) :1803-6  

 

 

Very important notice for export

Since 1rst of January 2012 

The production and the export of the clinical laboratory diagnostic kits RIA and ELISA 

are transferred to the company : Asbach Medical Products GmbH

Tel: + 49 62 62 91 74 02 - Fax: + 49 62 62 91 76 99 - Email: info@amp-asbach.com

If any problem please do not hesitate to contact us.

Last updating 14/12/11